Navigation Links
IRIDEX Reports 2012 Third Quarter Results
Date:11/1/2012

MOUNTAIN VIEW, Calif., Nov. 1, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 29, 2012.  

  • Ophthalmology revenues in the third quarter were $7.9 million, compared to $8.3 million in the prior year period.
  • Gross margin for the third quarter improved to 49.6%, compared to 48.3% in the prior year period and up from 48.7% in the second quarter.
  • Operating expenses, excluding one-time severance expenses of $0.7 million were $3.8 million in the third quarter compared to $3.7 million in the prior year period and $4.5 million in the second quarter.
  • Loss from continuing operations for the third quarter was $0.6 million or $0.06 per diluted share, compared with income from continuing operations of $0.3 million, or $0.02 per diluted share, in the prior year period.  
  • Guidance for fourth quarter: The Company expects to achieve revenues between $8.4 million and $8.7 million, gross margins between 49% and 51% and operating expenses between $4.0 million and $4.2 million.  The Company anticipates generating operating income in the fourth quarter.
  • Interim CEO William M. Moore said, "IRIDEX implemented a number of important strategic and operational realignments during the third quarter.  This included a management change at the end of August and the subsequent elimination or reassignment of several senior executive positions.  These personnel changes have been accompanied by an assessment of the Company's revenue and spending plans in order to give priority to investments that have the potential to deliver significant near term shareholder return via either new revenues or improved efficiencies.  The combination of changes was designed to improve performance and accountability at all levels of the organization."

    Moore continued, "Going forward, we plan to deliver shareholder value in three principal ways.  First, we will return the Company to profitability and thereafter operate the business to be consistently profitable. Second, we will take advantage of our strong position in the market to be opportunistic in acquiring or partnering with ophthalmic companies that have developed excellent technologies. Third, we will deploy cash from our strong balance sheet and profitable operations to directly benefit our shareholders through our share buyback program."

    During the third quarter, the Company repurchased 76,429 shares at an average price of $3.65. In total, the Company has repurchased 241,000 shares at an average price of $3.82. In May 2012, the Board of Directors approved an extension of the Company's share repurchase program through March 2013 and an increase in the amount of cash available for the program to a total of $4 million.  Moore said, "We are exploring all avenues open to the Company to make the ongoing buyback program more effective."

    The preceding commentary relates to the results of the Company's continuing ophthalmology business. In February 2012, the Company sold its aesthetics laser business and the financial statements reflect the results of its aesthetics laser business as discontinued operations.

    Nine Month 2012 Business Highlights

  • The Company's Board of Directors named medical device industry veteran William M. Moore as interim President and Chief Executive Officer, effective August 29, 2012.  The Board also appointed James Mackaness as Chief Operating Officer. Mackaness will continue to serve in his role as the Company's Chief Financial Officer and Moore will continue to serve as Chairman of the Board of Directors during his tenure as Interim Chief Executive Officer. 
  • The Company launched a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
  • The Company announced the first use of MicroPulse Laser Therapy (MPLT), using the IQ 577 laser coupled with EndoProbe® instrumentation. This is the first time tissue-sparing laser therapy has been delivered through an intraocular fiber-optic probe in a surgical setting demonstrating the feasibility of intraocular MPLT approaches.
  • The Company closed the sale of its aesthetics business to Cutera, Inc. for approximately $5.1 million. The sale allows the resources of the entire organization to now focus on the substantial and growing opportunity in the worldwide retina and glaucoma markets.
  • Conference Call IRIDEX management will conduct a conference call later today, Thursday, November 1, 2012 at 5:00 p.m. Eastern Time.  Interested parties may access the live conference call via telephone by dialing (877) 941-1465 (U.S.) or (480) 629-9724 (International) and quoting Conference ID 4572831, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, November 1, 2012 through Thursday, November 8, 2012 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4572831. In addition, later today an archived version of the webcast will be available on the Company's website at www.iridex.com.

    About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at http://www.iridex.com/.

    Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of markets in which the Company operates, the success of the Company's marketing and sales efforts,  MicroPulse laser therapy, the Company's growth strategy, the Company's acquisition strategy, sales revenue growth, operational plans, profitability, the Company's projected fiscal 2012 financial results and the Company's share repurchase program. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31 and June 30, 2012 which were filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

    TABLES FOLLOW

     IRIDEX Corporation

    Condensed Consolidated Statements of Operations

    (In thousands, except per share data)

    (unaudited)Three Months EndedNine Months EndedSeptember 29,October 1,September 29,October 1,2012201120122011Total revenues

    $
    7,881$
    8,258$
    24,631$
    24,539Cost of revenues

    3,9704,26812,62312,527Gross profit

    3,9113,99012,00812,012Operating expenses:Research and development

    1,0068943,2942,747Sales and marketing

    1,8751,7475,8615,311General and administrative

    1,6091,0884,0183,193Total operating expenses

    4,4903,72913,17311,251(Loss) income from continuing operations

    (579)261(1,165)761Legal settlement

    --800800Other expense, net

    (117)(53)(192)(46)(Loss) income from continuing operations before income taxes

    (696)208(557)1,515(Benefit from) provision for income tax expense

    (141)(48)(134)175(Loss) income from continuing operations

    (555)256(423)1,340(Loss) income from discontinued operations, net of tax

    (190)93(413)484Gain on sale of discontinued operations, net of tax

    --2,032-(Loss) income from discontinued operations, net of tax

    (190)931,619484Net (loss) income

    $
    (745)$
    349$
    ,196$
    ,824Net (loss) income per share: Basic:  Continuing operations

    $(0.06)$0.03$(0.05)$0.15  Discontinued operations

    (0.02)0.010.180.05  Net (loss) income

    $(0.08)$0.04$0.13$0.20 Diluted:  Continuing operations

    $(0.06)$0.02$(0.05)$0.13  Discontinued operations

    (0.02)0.010.180.05  Net (loss) income

    $(0.08)$0.03$0.13$0.18Weighted average shares used in computing net (loss) income per share:   Basic

    9,0058,9658,9748,963  Diluted

    9,00510,2538,97410,233 

    IRIDEX Corporation

    Condensed Consolidated Balance Sheets

    (In thousands, except share and per share data)

    (unaudited)September 29,December 31,20122011AssetsCurrent Assets:Cash and cash equivalents

    $
    3,734$
    ,789Accounts receivable, net

    5,4965,551Inventories, net

    7,5426,659Prepaids and other current assets

    1,117464Current assets of discontinued operations

    7246,043Total current assets

    28,61329,506Property and equipment, net

    468325Intangible assets, net

    602745Goodwill

    533533Other long-term assets

    219199Non-current assets of discontinued operations

    4841Total assets

    $
    30,439$
    32,149Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable

    $
    ,529$
    ,580Accrued compensation

    1,9871,180Accrued expenses

    1,0001,920Accrued warranty

    528556Deferred revenue

    8611,014Current liabilities of discontinued operations

    672,663Total current liabilities

    5,9728,913Long-term liabilities:Other long-term liabilities

    706810Total liabilities

    6,6789,723Stockholders' equity:Convertible preferred stock

    55Common stock

    9492Additional paid-in capital

    42,71242,032Accumulated other comprehensive loss

    -(35)Treasury stock, at cost

    (1,656)(1,078)Accumulated deficit

    (17,394)(18,590)Total stockholders' equity

    23,76122,426Total liabilities and stockholders' equity

    $
    30,439$
    32,149 

     


    '/>"/>
    SOURCE IRIDEX Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
    2. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
    3. IRIDEX Reports 2012 Second Quarter Results
    4. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
    5. IRIDEX Reports 2012 First Quarter Results
    6. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
    7. Masimo Reports Third Quarter 2012 Financial Results; Board Declares Special Cash Dividend of $1.00 per Share
    8. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
    9. MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results
    10. Da Vinci Robot May Cause Serious Complications for Patients Receiving Hysterectomies and Other Procedures, Reports Surgical News
    11. Cumberland Pharmaceuticals Reports Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
    (Date:5/3/2016)... Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further ...    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
    (Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
    Breaking Medicine Technology:
    (Date:5/5/2016)... ... May 05, 2016 , ... ... (LAIs), today announced a development collaboration with the Australian critical medicine company, ... such as schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral ...
    (Date:5/5/2016)... ... ... Einstein Medical is proud to announce that it has created ... at the 2016 ASCRS/ASOA Symposium and Congress, which takes place in New Orleans, LA ... Surgery and the American Society of Ophthalmic Administrations will be held at the Ernest ...
    (Date:5/5/2016)... ... ... from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team Semper ... Mountain Bike Camp, hosted in conjunction with WTB and Cannondale in ... who’ll share pro tips with the injured veterans as they rip down some of the ...
    (Date:5/5/2016)... Francisco, CA (PRWEB) , ... ... ... intensive lectures and hands-on exercises, the Wharton Seminars for Business Journalists ... a better understanding of key business and economic issues.  This one-day program ...
    (Date:5/5/2016)... ... ... Derrin Doty Group has unveiled the latest charity campaign in their ongoing community ... The insurance provider’s caring team has been so moved by the sudden death of ... the flu, that they have decided to extend their original campaign. Compassionate community members ...
    Breaking Medicine News(10 mins):